DRC Begins Ebola Vaccine Trial with First Participants Receiving Doses
WHO Director of Science for Health Meg Doherty told reporters in Geneva that the study, named TUMAINI, which means "hope" in Swahili, was launched on Friday.
The trial is evaluating Ervebo, a vaccine already demonstrated to be safe and effective against Ebola caused by the Zaire virus. However, its effectiveness against Bundibugyo virus disease has not yet been established.
Doherty explained that the research aims to determine whether vaccination can lower the risk of severe illness or death, rather than prevent people from becoming infected.
Researchers are following a ring-vaccination strategy, targeting individuals who have had close contact with confirmed Ebola patients or may otherwise have been exposed to the virus.
Two vaccination rings have been established so far, while preparations are underway to create additional groups. Eligible individuals may receive the vaccine between one and 21 days following exposure, although it remains uncertain whether the timing of vaccination will influence the results.
"We do not yet know for certain when results will begin to emerge. We expect it will take several months," Doherty said.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
